Pembrolizumab in Combination With Lenvatinib in Patients With Advanced Biliary Tract Carcinoma

Advanced Biliary Tract Carcinoma Clinical Trial

Official title:

A Single Arm Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With Advanced Biliary Tract Carcinoma After Progression on Standard Systemic Therapy

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04550624
• Other study ID #: 2020-0001
• Status: Recruiting
• Phase: Phase 2
• Start date: August 9, 2021
• Est. completion date: December 2025

Study information

• Verified date: January 2024
• Source: Shanghai Jiahui International Hospital
• Contact: Flora Yan
• Phone: +86 (21) 5339 3382
• Email: mengchen.yan[@]jiahui.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The prognosis for unresectable and metastatic biliary tract cancers (BTCs) including cholangiocarcinoma is poor with first line gemcitabine and cisplatin offering a median overall survival of 11.7 months. There is no standard second- or third-line therapy for advanced BTC, and this represents an unmet medical need for novel therapies. The immune system plays a critical role in the development of Advanced Biliary Tract Carcinoma (BTC) and chronic inflammation is a common underlying risk factor for BTC. Vascular endothelial growth factor (VEGF) signaling in BTC may lead to an immune suppression via inadequate tumor antigen presentation and an impaired T cell-mediated immune response directed against tumor antigens. Lenvatinib significantly decreased the population of immunosuppressive tumor-associated macrophages and increased interferon-γ-producing cluster of differentiation 8+ (CD8+) T cells. Addition of programmed cell death protein 1 (PD-1)/programmed death-ligand (PD-L1) inhibitors helps reverse VEGF-mediated immune suppression, restore T cell function, and promote T cell tumor infiltration. The combination of lenvatinib and pembrolizumab has demonstrated promising activity with manageable adverse events in various solid tumor types.

The investigators will assess the efficacy and safety of the combination of pembrolizumab and lenvatinib in patients with advanced BTC who failed standard therapy in this phase II study.

Description:

Title: A Single Arm Phase II Study of Pembrolizumab in combination with Lenvatinib in Patients with Advanced Biliary Tract Carcinoma after Progression on Standard Systemic Therapy Study Description: The prognosis for unresectable and metastatic biliary tract cancers (BTCs) including cholangiocarcinoma is poor with first line gemcitabine and cisplatin offering a median overall survival of 11.7 months. There is no standard second- or third-line therapy for advanced BTC, and this represents an unmet medical need for novel therapies. The immune system plays a critical role in the development of Advanced Biliary Tract Carcinoma (BTC) and chronic inflammation is a common underlying risk factor for BTC. VEGF signaling in BTC may lead to an immune suppression via inadequate tumor antigen presentation and an impaired T cell-mediated immune response directed against tumor antigens. Lenvatinib significantly decreased the population of immunosuppressive tumor-associated macrophages and increased interferon-γ-producing CD8+ T cells. Addition of PD-1/PD-L1 inhibitors helps reverse VEGF-mediated immune suppression, restore T cell function, and promote T cell tumor infiltration. The combination of lenvatinib and pembrolizumab has demonstrated promising activity with manageable adverse events in various solid tumor types.

The investigators will assess the efficacy and safety of the combination of pembrolizumab and lenvatinib in patients with advanced BTC who failed standard therapy in this phase II study.

Objectives and Endpoints:

Primary Objective: Evaluate the objective response rate (ORR) (RECIST1.1) of lenvatinib in combination with pembrolizumab in patients with advanced BTC after progression on standard systemic therapies Secondary Objective: Evaluate the safety and tolerability of lenvatinib+pembrolizumab in this population; Determine the duration of response (DOR), progression free survival (PFS), and overall survival (OS); Determine the ORR, PFS and OS of subgroups stratified by molecular signatures (tumor mutation burden, PD-L1 expression, microsatellite instability (MSI) status, isocitrate dehydrogenase (IDH) or FGFR mutation/fusion status) in a pre-planned post-hoc analysis; Define molecular correlates of response, including circulating biomarkers and tumor tissue biomarkers Study Population: The study will enroll 40 patients who have unresectable or metastatic, histologically-confirmed advanced BTC. Both male and female patients age of 18 years or older who have failed standard systemic therapy for advanced BTC with measurable disease, adequate bone marrow reserve and hepatic/renal function, and ECOG performance status (PS) 0-1 could be eligible to participate in the study after completing the study enrollment screening tests and procedures.

Phase: II Description of Sites/Facilities Enrolling Participants: The study will be conducted at Jiahui International Cancer Center, Shanghai Jiahui International Hospital, in collaboration with Zhongshan Hospital.

Study treatment/Intervention: Each cycle is defined as 21 days treatment of Pembrolizumab in combination with Lenvatinib. Treatment will be administered on an outpatient basis:

Pembrolizumab 200mg IV day 1 of every 21 day-cycles; Lenvatinib 20mg PO once daily for 21-day cycles Study Duration: 24-36 months Participant Duration: up to 24 months

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 40
• Est. completion date: December 2025
• Est. primary completion date: December 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients must meet the following criteria in order to be eligible to participate in the study:

1. Unresectable or metastatic, histologically-confirmed advanced BTC (excluding periampullary cancer)

2. Failed standard systemic therapy for advanced BTC due to progression of disease or toxicity

3. Measurable disease

4. Prior chemoembolization, radiofrequency ablation, or radiation to the liver is allowed as long as the patient has measurable disease outside the chemoembolization or radiation area or measurable progression at the site of chemoembolization or radiation

5. ECOG Performance status = 1

6. Life expectancy > 3 months

7. Adequate renal function as defined by Cr = 1.5 upper limit of normal (ULN) or glomerular filtration rate (GFR) = 60 mL/min/1.73 m2

8. Adequate hepatic function as defined by bilirubin = 2.5 x ULN and alanine transaminase (ALT) and aspartate aminotransferase (AST) = 5x ULN

9. Adequate bone marrow reserve as evidenced by ANC > 1500/mcl, Plts >75,000/mcl, Hgb = 9.0g/dl

10. Prothrombin time / Partial thromboplastin time (PT/PTT) <1.5x ULN

11. Urine Protein: Creatinine ratio of <1, if protein is > 2+ on urinalysis

12. Age = 18 years

13. Participants with past or ongoing hepatitis C virus (HCV) infection are eligible for the study. Treated participants must have completed their treatment at least 1 month prior to starting study intervention. Untreated or incompletely treated HCV participants may initiate anti-viral therapy for HCV if liver function remains stable for at least 3 months on study intervention

14. Participants with controlled hepatitis B are eligible for the study, as long as they meet the following criteria:

Participants with chronic hepatitis B virus (HBV) infection, defined as HBsAg positive and/or detectable HBV DNA, must be given antiviral therapy for HBV for at least 4 weeks prior to the first dose of study intervention and HBV viral load must be less than 100 IU/ml. prior to the first dose of study treatment. Participants on active HBV therapy with viral loads under 100 IU/ml. should stay on the same therapy throughout study intervention. Antiviral therapy after completion of study intervention should follow local guidelines.

15. Participants with clinically resolved HBV infection, defined as HBsAg negative and anti-hepatitis B core antigen (HBc) positive, and who have an undetectable HBV viral load at screening should be checked every 6 weeks for HBV viral load and treated for HBV if viral load is over 100 IU/ml. Antiviral therapy after completion of study intervention should follow local guidelines.

Exclusion Criteria:

• Patients who exhibit any of the following conditions at screening will not be eligible to be enrolled to the study:

1. Prior treatment with other VEGF-R directed therapies

2. Periampullary cancer

3. Major surgery or radiation within the 4 weeks prior to enrollment; is currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of registration. The treated patients must recover from their relevant treatment(i.e. to=1 grade or baseline) and from any AEs caused by any previous treatment

4. Uncontrolled hypertension defined by systolic blood pressure (SBP)>150 or diastolic blood pressure (DBP)>90 despite titration of anti-hypertensive medications

5. Active, known or suspected autoimmune disease

6. Congestive heart failure or symptomatic coronary artery disease within 3 months prior to enrollment

7. Cerebrovascular accident within prior 6 months

8. Clinically significant hemorrhage, bleeding event, or thromboembolic disease within six months

9. History of bowel perforation

10. History of (non-infectious) pneumonitis that required steroids or currently has pneumonitis

11. Known history of HIV infection

12. Severely impaired lung function or history of interstitial lung disease

13. Concurrent malignancy (other than adequately treated non-melanoma skin cancer, superficial transitional cell carcinoma of the bladder, and cervical CIS) diagnosed within the past 5 years or any currently active malignancy

14. Positive serum pregnancy test within 72 hours of first dosing of study treatment

15. History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator

Related Conditions & MeSH terms

• Advanced Biliary Tract Carcinoma
• Carcinoma

Intervention

Drug:
• Pembrolizumab Injection [Keytruda]
200mg IV on day 1 of each cycle
• Lenvatinib Mesylate
20mg PO daily days 1-21 of each cycle

Locations

Country	Name	City	State
China	Shanghai Jiahui International Hospital	Shanghai	Shanghai
China	Shanghai Zhongshan Hospital	Shanghai	Shanghai

Sponsors (2)

Lead Sponsor	Collaborator
Shanghai Jiahui International Hospital	Shanghai Zhongshan Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Evaluation of ORR	Evaluate the objective response rate (ORR) (RECIST1.1) of lenvatinib in combination with pembrolizumab in patients with advanced BTC after progression on standard systemic therapies	up to 36 months
Secondary	All participants who receive at least one dose of study treatment will be evaluable for safety and tolerability through the monitoring of serious and non serious AEs, defined and graded according to NCI CTCAE v5.0.	All participants who receive at least one dose of study treatment will be evaluable for safety and tolerability in this study through the monitoring of all serious and non serious AEs, defined and graded according to NCI CTCAE v5.0 from the time of their first treatment.	up to 36 months
Secondary	Duration of Overall Response (DOR)	The duration of overall response is measured from the time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrence or PD is objectively documented, taking as reference for PD the smallest measurements recorded since the treatment started. Patients who do not relapse will be censored at the day of their last tumor assessment.	up to 36 months
Secondary	Progression-Free Survival (PFS)	Progression-Free Survival (PFS) is defined as the duration of time from start of treatment to time of objective disease progression or death from any cause without evidence of disease progression, whichever comes first.	up to 36 months
Secondary	Overall Survival (OS)	Overall Survival (OS) is defined as the duration of time from start of treatment to time of death.	up to 36 months
Secondary	Objective Response Rate (ORR) of subgroups burden	Determine the ORR of subgroups stratified by molecular signatures (tumor mutation burden, PD-L1 expression, MSI status, FGFR mutation/fusion status) in a pre-planned post-hoc analysis	up to 36 months
Secondary	Progression-Free Survival (PFS) of subgroups burden	Determine the PFS of subgroups stratified by molecular signatures (tumor mutation burden, PD-L1 expression, MSI status, FGFR mutation/fusion status) in a pre-planned post-hoc analysis	up to 36 months
Secondary	Overall Survival (OS) of subgroups burden	Determine the OS of subgroups stratified by molecular signatures (tumor mutation burden, PD-L1 expression, MSI status, FGFR mutation/fusion status) in a pre-planned post-hoc analysis	up to 36 months